The pros and cons of new treatments for type 2 diabetesBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7611.121-c (Published 19 July 2007) Cite this as: BMJ 2007;335:121
Incretins are gut peptides that help regulate glucose metabolism by augmenting the release of insulin. Since 2005, the US Food and Drug Administration has licensed two new classes of drug exploiting this pathway for treating adults with type 2 diabetes …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial